Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $284.00

Krystal Biotech (NASDAQ:KRYS) had its price objective boosted by Guggenheim from $224.00 to $284.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

KRYS has been the subject of several other research reports. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Jefferies Financial Group boosted their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. HC Wainwright reissued a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 18th. Finally, Citigroup boosted their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $275.64 on Wednesday. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $298.30. The business has a 50 day moving average price of $268.99 and a 200 day moving average price of $214.38. The company has a market capitalization of $8.06 billion, a P/E ratio of 40.24 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. As a group, research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 116,611 shares of company stock worth $30,008,839 in the last three months. 13.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. increased its position in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares in the last quarter. Bessemer Group Inc. boosted its position in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the period. AdvisorNet Financial Inc acquired a new stake in Krystal Biotech in the 3rd quarter valued at $30,000. Salomon & Ludwin LLC purchased a new position in Krystal Biotech in the third quarter valued at about $33,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.